Bio-Rad Laboratories (BIO) Valuation Check After New MicroVal Approval For Listeria Testing Kits

Bio-Rad Laboratories (BIO) is back in focus after MicroVal approved its EZ-Check Listeria spp. and EZ-Check Listeria monocytogenes Kits, validating their compliance with ISO 16140-2 standards for food and environmental testing.

See our latest analysis for Bio-Rad Laboratories.

Despite a 1-day share price return of down 4.28% and a 7-day share price return of down 3.65%, Bio-Rad’s 30-day share price return of 15.73% and 1-year total shareholder return of 30.48% suggest momentum has picked up recently, while longer term total shareholder returns over three and five years remain weak.

If this kind of regulatory milestone has your attention, it could be a good moment to see what else is setting up for potential growth and resilience through the 38 healthcare AI stocks

With Bio-Rad stock trading at about a 1% discount to the average analyst price target and an intrinsic value estimate that sits slightly above the market price, the key question is whether investors are still missing something here or whether markets are already pricing in future growth.

Most Popular Narrative: 50% Overvalued

The most followed narrative pegs Bio-Rad’s fair value at $293, just under the last close of $294.32, and leans heavily on modest growth and higher future margins to justify that level.

Resilience and stable growth in consumables and reagents, demonstrated by high single-digit growth, especially in the face of delayed academic and instrument funding, are shifting Bio-Rad's sales mix toward higher-margin, recurring revenues, supporting overall profitability and cash flow stability.

Read the complete narrative.

Curious what is driving that fair value so close to today’s price? The narrative leans on steady revenue gains, fatter margins, and a richer earnings multiple that assumes investors will pay up for consistency.

Result: Fair Value of $293 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, continued softness in instrument demand, along with pressure on Clinical Diagnostics in markets like China, could easily upset the margin and earnings story investors are backing.

Find out about the key risks to this Bio-Rad Laboratories narrative.

Next Steps

With mixed signals across growth, margins, and valuation, do you feel the balance of optimism and concern is justified or overdone? Act while the data is fresh in mind and weigh both sides by checking the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Bio-Rad has sharpened your focus, do not stop here. Broaden your watchlist now so you do not miss other compelling setups across the market.

• Scan for quality at a discount by checking the 48 high quality undervalued stocks.
• Prioritize resilience and sleep-better-at-night holdings through the 63 resilient stocks with low risk scores.
• Hunt for lesser known opportunities with solid fundamentals using the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com